Micah Fisher
Expertise in
11
conditions

Dr. Micah Fisher

Pulmonary Medicine
Emory Clinic At 1365 Clifton Road
1365 Clifton Road Northeast, BldgA, 
Atlanta, GA 
Offers Telehealth
27 Years of Experience
Expertise in
11
conditions
Emory Clinic At 1365 Clifton Road
1365 Clifton Road Northeast, BldgA, 
Atlanta, GA 

Overview

Micah Fisher is a Pulmonary Medicine provider in Atlanta, Georgia. Dr. Fisher has been practicing medicine for over 27 years is highly rated in 11 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Acute Interstitial Pneumonia, and Interstitial Lung Disease.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Wake Forest University, 1999.0

Residency

University of Pennsylvania

Specialties

Pulmonary Medicine

Licenses

Internal Medicine in GA

Board Certifications

American Board Of Internal Medicine, 2007

Fellowships

Johns Hopkins Bayview Medical Center

Hospital Affiliations

Emory University Hospital Midtown
Emory Johns Creek Hospital
Emory University Hospital
Saint Joseph's Hospital Of Atlanta, Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Good Samaritan Society
  • MEDICARE SNP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Emory Clinic at 1365 Clifton Road
1365 Clifton Road Northeast, BldgA, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Drug: Treprostinil Inhalation Powder
Study Phase: Phase 1
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

19 Total Publications

BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension.
BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension.
Journal: Respiratory medicine
Published: June 18, 2025
Similar Doctors
Srihari Veeraraghavan
Expertise in
15
conditions
Dr. Srihari Veeraraghavan
Pulmonary Medicine
Expertise in
15
conditions
Dr. Srihari Veeraraghavan
Pulmonary Medicine

Emory Clinic At 1365 Clifton Road

1365 Clifton Road Northeast, BldgA, 
Atlanta, GA 
 (0.3 miles away)
404-778-3261
Experience:
34+ years
Languages Spoken:
English, Tamil
See accepted insurances

Srihari Veeraraghavan is a Pulmonary Medicine provider in Atlanta, Georgia. Dr. Veeraraghavan has been practicing medicine for over 34 years is highly rated in 15 conditions, according to our data. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, Sarcoidosis, and Lung Transplant.

David C. Neujahr
Expertise in
10
conditions
Dr. David C. Neujahr
Pulmonary Medicine
Expertise in
10
conditions
Dr. David C. Neujahr
Pulmonary Medicine

Emory Transplant Center

1365 Clifton Road Northeast, BldgB, 
Atlanta, GA 
 (0.3 miles away)
855-366-7989
Experience:
27+ years
Languages Spoken:
English, Spanish
See accepted insurances

David Neujahr is a Pulmonary Medicine provider in Atlanta, Georgia. Dr. Neujahr has been practicing medicine for over 27 years is highly rated in 10 conditions, according to our data. His top areas of expertise are Pulmonary Fibrosis, Bronchiolitis Obliterans, Acute Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, and Lung Transplant.

Charles B. Hartley
Expertise in
37
conditions
Dr. Charles B. Hartley
Pulmonary Medicine
Expertise in
37
conditions
Dr. Charles B. Hartley
Pulmonary Medicine

Piedmont Physicians Pulmonary And Sleep Medicine Buckhead

275 Collier Road NW, Suite 300, 
Atlanta, GA 
 (3.8 miles away)
404-350-0009
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

C. Bryce Hartley II M.D., FCCP, earned his medical degree from Wake Forest University in Winston-Salem, N.C. He completed his internal medicine residency at Tulane University Medical Center. His pulmonary residency and pulmonary and critical care medicine fellowships were completed at Georgetown University. He received his undergraduate degree in chemistry from the University of North Carolina. Prior to joining Piedmont Physicians, Dr. Hartley was in practice with Georgia Lung Associates. He is board certified in pulmonary medicine. Dr. Hartley has special interest in pleural disease, cough syndromes and airway disorders including asthma, COPD, bronchiectasis and bronchiolitis. Dr. Hartley welcomes new patients and accepts most insurance plans. Dr. Hartley is highly rated in 37 conditions, according to our data. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Pneumonia, Acute Interstitial Pneumonia, and Advanced Bronchoscopy.

Frequently Asked Questions about Dr. Micah Fisher

How do I make an appointment with Dr. Micah Fisher?

You can book an appointment with Dr. Micah Fisher by calling their office at 404-778-3261. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Micah Fisher a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Micah Fisher is classified as an Elite expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Micah Fisher specialize in?

While Dr. Micah Fisher is a Pulmonary Medicine, they have specific expertise in Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, and Acute Interstitial Pneumonia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. Micah Fisher participate in research or clinical trials?

Yes. Dr. Micah Fisher has published 19 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Micah Fisher's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Micah Fisher accept my insurance?

Dr. Micah Fisher accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 404-778-3261 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fisher's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile